Migraine affects over 10% of people worldwide | eNeura

About Migraine

graphic shows electrical storm in the brain

Migraine is a chronic and often debilitating neurological disease.

Much more than a bad headache, migraine is a serious disease with significant impact on individuals and on society as a whole. It affects more than 10% of the population worldwide.2

Learn more

Important studies

  • Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial.

    Link to journal
  • Use of single pulse TMS (sTMS) to treat migraine with medication overuse.

    View full text
chart shows patient support in eNeura migraine care community

Insight, understanding, and empathy

Support and information for people who suffer from migraine is available from healthcare professionals, from scientific researchers, and from patient organizations and advocacy groups.

Learn more

About 70% of migraine patients are not satisfied with or cannot tolerate the side effects associated with medications.3

Now, the sTMS mini by eNeura is here: a clinically proven, non-drug option for migraine relief.

Customer Care

eNeura Customer Care is available to help you with answers to any questions about delivery of the sTMS mini, prescription renewal, traveling with your device, and other practical issues. They are also your first point of contact to reach eNeura Access Consultants and Clinical Education Specialists.

To get the support you need, call:

800-366-8355
8:00 AM to 5:00 PM (Pacific Time), Monday ‒ Friday

Or email customercare@eneura.com

Information provided by the eNeura Migraine Care Team is not a substitute for your doctor’s instructions. In case of immediate or urgent medical concerns, always contact your doctor or Emergency Services.

My gain

I am able to ride my bike regularly.
— 69-year-old female
Indication: The sTMS mini™ by eNeura® is indicated for the acute and prophylactic treatment of migraine headache.
References

  1. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754-762.
  2. Lipton RB, Bigal ME, Diamond M. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349.
  3. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39(suppl 2):S20-S26.
  4. Lipton RB, Bigal ME. The epidemiology of migraine. Am J Med. 2005;118(suppl 1):3S-10S.
  5. Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N Eng J Med. 2002;346(4):257-270.
  6. Goadsby PJ. Pathophysiology of migraine. Ann Indian Acad Neurol. 2012;15(suppl 1):15S-22S.
  7. Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value Health. 2009;12(1):55-64.
  8. All-Party Parliamentary Group on Primary Headache Disorders. Headache Disorders – not respected, not resourced. London, UK: House of Commons; 2010.